ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elinzanetant

Also written as “Elinzanetant (BAY3427080)”, “GSK1144814” and “BAY3427080”.

Its studies are mostly in Hot Flashes · Schizophrenia, led by 2 companies.

Drug pageElinzanetant: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 26, 202124 company-led studies, 2 open or runningNext primary completion: Jan 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayerits history only212 open or runningphase 3since Aug 26, 2021Aug 3, 2016Jan 22, 2027phase 1 · NCT07762287
GlaxoSmithKline30 open or runningphase 1since Mar 4, 2010Mar 4, 2010none ahead

Also a collaborator on its studies: Nerre Therapeutics and Quotient Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 4, 2010First study: phase 1 study in SchizophreniaFirst studyNCT01090440 · 16 enrolled · Australia
  2. Aug 30, 2010Phase 1 study in SchizophreniaNCT01209039 · 41 enrolled · United Kingdom
  3. Jun 9, 2011Phase 1 study in SchizophreniaNCT01381419 · 21 enrolled · United Kingdom
  4. Dec 9, 2019Named elinzanetantINNProposed as its International Nonproprietary Name in WHO's List 122 · before, GSK1144814, BAY3427080

TargetBeta

“An orally bioavailable neurokinin/tachykinin 1 receptor (NK1-receptor; NK1R; NK-1R) and NK3 receptor (NK-3R; NK3R) antagonist, that may be used to treat vasomotor symptoms in menopausal woman”NCIt, by rule
“Neurokinin 1 receptor antagonist; Neurokinin 3 receptor antagonist”ChEMBL 37, by rule

Studies

All 3 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01381419Schizophrenia · United Kingdom1CompletedApr 1, 200921
NCT01209039Schizophrenia · United Kingdom1CompletedOct 25, 200941
NCT01090440Schizophrenia · Australia1CompletedOct 9, 200916

How it is read

Names in the registry

  • “Elinzanetant (BAY3427080)”, 15 entries
  • “GSK1144814”, 7 entries
  • “BAY3427080”, 2 entries
  • “Elinzanetant (BAY 3427080) treatment A”, 1 entry
  • “Elinzanetant (BAY 3427080) treatment B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.